- Home
- RIME vs PALI Comparison
RIME vs PALI Comparison
Compare RIME & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIME
- PALI
- Stock Information
- Founded
- RIME 1982
- PALI 1996
- Country
- RIME United States
- PALI United States
- Employees
- RIME N/A
- PALI N/A
- Industry
- RIME
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIME
- PALI Health Care
- Exchange
- RIME NYSE
- PALI Nasdaq
- Market Cap
- RIME 4.9M
- PALI 4.1M
- IPO Year
- RIME 1994
- PALI N/A
- Fundamental
- Price
- RIME $0.41
- PALI $3.57
- Analyst Decision
- RIME
- PALI Strong Buy
- Analyst Count
- RIME 0
- PALI 1
- Target Price
- RIME N/A
- PALI $22.50
- AVG Volume (30 Days)
- RIME 10.6M
- PALI 20.5K
- Earning Date
- RIME 11-19-2024
- PALI 11-08-2024
- Dividend Yield
- RIME N/A
- PALI N/A
- EPS Growth
- RIME N/A
- PALI N/A
- EPS
- RIME N/A
- PALI N/A
- Revenue
- RIME $37,788,657.00
- PALI N/A
- Revenue This Year
- RIME N/A
- PALI N/A
- Revenue Next Year
- RIME N/A
- PALI N/A
- P/E Ratio
- RIME N/A
- PALI N/A
- Revenue Growth
- RIME 24.99
- PALI N/A
- 52 Week Low
- RIME $0.35
- PALI $3.14
- 52 Week High
- RIME $1.97
- PALI $22.35
- Technical
- Relative Strength Index (RSI)
- RIME N/A
- PALI 50.95
- Support Level
- RIME N/A
- PALI $3.16
- Resistance Level
- RIME N/A
- PALI $3.81
- Average True Range (ATR)
- RIME 0.00
- PALI 0.21
- MACD
- RIME 0.00
- PALI 0.03
- Stochastic Oscillator
- RIME 0.00
- PALI 63.08
About RIME ALGORHYTHM HOLDINGS INC
Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.